• Tamoxifen treatment mimicked the effects of estradiol in many parameters analyzed.
Introduction
Tamoxifen (TAM) is a triphenethylene derivative drug that is widely used for the treatment of all stages of breast cancer [1] , reducing the incidence of breast cancer in both pre and postmenopausal Physiology & Behavior 119 (2013) [17] [18] [19] [20] [21] [22] [23] [24] women at elevated risk [2, 3] . TAM is a selective estrogen receptor modulator (SERM), a class of drugs that act as estrogen receptor agonists or antagonists, depending on the target tissue [4] . TAM behaves like an estrogen antagonist in mammary tissue while it mimics the effects of estrogen in other tissues, for example the uterus, cardiac and bone tissues [5] [6] [7] . However, it is not yet understood whether TAM has estrogenic or antiestrogenic activities in the brain.
Estrogens exert their physiological effects through two estrogen receptor (ER) subtypes, ERα and ERβ, which belong to the nuclear receptor family of ligand-activated transcription factors. ER has two 'activation' domains within the receptor, which facilitate the interaction of the ER with the transcription apparatus-activation function-1 (AF-1) and activation function-2 (AF-2). Both ERα and ERβ contain an AF-2 domain, but unlike ERα, ERβ seems to have a weaker AF-1 domain and depends more on the AF-2 for its transcriptional activation function [8, 9] . Furthermore, estrogen can act by non-genomic mechanisms via membrane ERs [10] . Evidence suggests that tamoxifen inhibits ER-AF-2 activity, and consequently acts as an antagonist in ERβ and has partial agonist activity in ERα [11] .
In addition to the estrogen effects on reproductive physiology, this ovarian hormone can modulate numerous brain neurotransmitters and neuromodulators, including the serotonergic, dopaminergic, neuropeptide Y and opioidergic systems, and consequently modulate cognitive functions, mood and the reward system [12] [13] [14] . It is well established that estradiol reduces food intake, body weight and improves lipid profile, possibly via the activation of ERα [15, 16] . These effects are probably due to an increase in the expression of anorexigenic genes and a decrease in the expression of orexigenic genes [17] . It is well known that tamoxifen mimics the effects of estradiol on food intake in rats [18, 19] .
Apart from these well-established effects of estradiol on food intake, the role of estradiol on palatable food is controversial and more complex [20, 21] . Palatable foods activate the reward system, thereby affecting ingestive behavior [22, 23] . The predilection for palatable foods and reward system activation is a basic and evolutionarilyconserved survival mechanism in animals and humans [24] . Foods rich in fat and sugar are attractive because such foods can be rapidly converted into energy [24, 25] . It has been demonstrated that the preference for palatable foods, including sweets, differs between males and females, and sweet preferences change across the menstrual cycle and during pregnancy [20, [26] [27] [28] [29] [30] . However, other studies report that estrogen does not affect behavioral responses to palatable foods [21, 31] .
Although it is well established that tamoxifen-treated animals demonstrate reduced body weight and standard chow intake, there is no information in the literature regarding tamoxifen treatment and the consumption of palatable food. On the other hand, humans have access to a variety of fat and sweet foods and it is known that many women experience weight gain during tamoxifen treatment for breast cancer. This is especially true for patients who were not overweight before diagnosis [19, 32] .
Therefore, the aim of this study was to investigate the effects of chronic treatment with estradiol and/or tamoxifen on feeding behavior in ovariectomized rats exposed to standard chow and palatable foods (Froot Loops® or chocolate). Additionally, parameters such as body weight, uterine weight and lipid profile were also measured.
Methods

Animals
We used 120 adult female (7-13 per group), Wistar rats (75 days of age at the beginning of the treatment), weighing between 180 and 220 g. Rats were housed in groups, with five rats per cage. Cages were made of Plexiglas material (65 × 25 × 15 cm) with the floor covered with sawdust. Animals were maintained on a standard dark-light cycle (lights on between 7:00 h and 19:00 h), at a room temperature of 21 ± 1°C. The rats had free access to food (standard rat chow) and water. All experimental procedures occurred during the light phase (10:00-15:00 h). All animal treatments were in accordance with the institutional guidelines and according to the recommendations of the International Council for Laboratory Animal Science (ICLAS), and all efforts were made to minimize animal suffering, as well as to reduce the number of animals used.
Surgery
All rats were ovariectomized or just underwent the surgery without removal of ovaries (SHAM group). Ovariectomies were performed under aseptic conditions. Rats were anesthetized with 60 mg/kg ketamine HCl (Dopalen: Agribrands, Campinas, SP, Brazil) and 16 mg/kg xylazine (Anasedan: Agribrands, Campinas, SP, Brazil) ip., and bilateral ovariectomy was performed with a single abdominal incision. The abdominal skin was then cut, the peritoneum was opened, both ovarian arteries were linked, and both ovaries were removed. The muscle and the skin were sutured [33] . Animals received one drop of acetaminophen (200 mg/ml, Paracetamol EMS, Hortolândia, SP, Brazil) after surgery as analgesic.
Treatments
After a recovery period of 10-15 days, the animals received Froot Loops® or chocolate in their home cage, 24 h before beginning the treatments in order to avoid taste aversion [34, 35] . The animals were divided into five groups: SHAM group (submitted to the surgery without removal of ovaries and received vehicle), OVX group (received vehicle), 17β-estradiol group (OVX that received 0.1 mg/kg), tamoxifen group (OVX that received 2 mg/kg) and E + TAM (OVX that received 0.1 mg/kg of 17β-estradiol + 2 mg/kg of tamoxifen). Tamoxifen (PharmaPlus -Porto Alegre, RS, Brazil) and estradiol (Sigma -St. Louis, MO, USA) was dissolved in vehicle: ethanol (10%), DMSO (5%) and 0.9% NaCl (85%). It is important to note that the 2 mg/kg dose of tamoxifen used in the present study is calculated to be the equivalent dose that is prescribed to patients (20 mg), based on surface area (mg/m 2 ) [34] . The 0.1 mg/kg dose of estradiol was chosen based on previous studies [36] , and mimics the proestrus phase of the estrous cycle [37] . Rats were injected (1 ml/kg ip.) daily between 1:00 pm and 3:00 pm until euthanasia. Body weight was monitored once a week.
Exposure to sweet food
The behavioral test was initiated 25 days after the first injection. Prior to all tests, rats were acclimatized to the experimental room for at least 30 min. This food behavior was conducted during the light phase [28, 38] , in order to measure the consumption of sweet food regardless of physiological mechanisms of hunger.
Rats were placed in a rectangular box (40 cm × 15 cm × 20 cm) with floor and side walls made of wood and a glass ceiling. Ten Froot Loops® (Kellogg's® pellets of wheat, cornstarch and sucrose) were placed in one extremity of the box. The animals were habituated to this environment for 5 days, for 3 min each day, under food restriction (receiving 80% of habitual ingestion). After the last habituation session, the animals were fed ad libitum and were exposed to a 3-min test session, 24 h later. Time spent to reach the food, time spent until beginning to eat and the number of ingested Froot Loops® were evaluated in each trial and in the test session. A protocol was established so that when the animals ate part of the Froot Loops® (e.g., 1/3 or 1/4), this fraction was considered [38] . This experiment could mimic the problem of women that gain weight during TAM treatment and diet in order to lose weight using food restriction.
Exposure to chocolate and standard chow
Twenty five days after the first injection, the animals were separated with two animals from the same group per cage and the consumption of standard chow was measured for two days. On the third day, the animals received standard chow and chocolate ad libitum, allowing them to choose between the two types of food for the next 7 days. The food was previously weighed and the remaining quantity was measured each day to evaluate consumption. See Table 1 for nutritional composition of these foods. To determine the caloric efficiency, (the amount of body weight gained as a result of caloric intake), the body weight gain (in milligrams) was divided by the total amount of kilocalories consumed over the 7 days [39] . For this experiment we used a different set of animals.
Blood collection and structure dissection
One day after the last behavioral procedure, animals were killed by decapitation after 14 h of fasting, between 09:00 h and 15:00 h, and the trunk blood was collected into tubes with EDTA, centrifuged at 4°C/1000 g, and plasma separated and stored at − 80°C until analysis of plasma lipids and plasma glucose. Uterus and retroperitoneal fat were carefully dissected and weighed using a scale with a precision of 0.0001 g.
Plasma lipids and glucose (Blood Biochemistry)
Total cholesterol (TC), high-density lipoprotein cholesterol (HDL), and triglyceride analyses were performed on EDTA plasma, collected from animals fasted for 14 h before blood collection. TC and triglycerides were measured by enzymatic method kits (Wiener Lab, Argentina). HDL concentrations were measured by a system for selective precipitation of Low and Very Low Density Lipoproteins (LDL and VLDL) and HDL cholesterol measurement in the supernatant, using an end point reaction, as described in the HDL Kit (Labtest, Brazil). Low-density lipoprotein cholesterol (LDL) was calculated using the Friedewald formula [40] . Plasma glucose was measured by the glucose oxidase method (Wiener Laboratories, Rosario, Argentina). All analyses were performed on a Spectra Max M5 autoanalyzer. For this experiment we used a different set of animals.
Statistical analyses
Data were analyzed using one-way or repeated-measures analysis of variance (ANOVA) and were expressed as means ± SEM. When indicated, a post-hoc Duncan multiple range test was performed. Significance levels for all measures were set at p b 0.05.
The timeline of the experimental procedures is shown below.
Results
Body weight, retroperitoneal fat and uterine weight
SHAM and OVX groups presented an increase in body weight (F(4,34) = 46.56, p b 0.001) and retroperitoneal fat (F(4,48) = 4.91, p = 0.002), and these effects were prevented by chronic administration of E, TAM or E + TAM (F(4,34) = 46.56, p b 0.001) ( Fig. 1 and Table 2 ).
Ovariectomized rats that received vehicle presented a significantly decreased uterine weight, when compared with the SHAM group. Those animals treated with estradiol demonstrated a significantly increased uterine weight, whereas TAM and E + TAM were unable to reverse the uterine weight loss due to ovariectomy (F(4,35) = 9.11, p b 0.001) ( Table 2 ).
Standard chow intake
We observed that the consumption of standard chow in the home cage was lower in groups treated with E, TAM or E + TAM (F(4,17) = 4.5, p = 0.01). The caloric efficiency of these groups was also lower (F(4,13) = 16.8, p b 0.0001), compared with the SHAM and OVX groups ( Fig. 2A and B) .
Sweet food ingestion
A one-way ANOVA, followed by the Duncan multiple range test, showed that the E, TAM and E + TAM groups took less time to reach the Froot Loops® (F(4,44) = 5.49, p b 0.001) (Fig. 3A) and start to eat (F(4,41) = 2.73, p = 0.001) (Fig. 3B ). E, TAM and E + TAM increased their intake of Froot Loops® (F(4,41) = 5.58, p = 0.01), compared to the SHAM and OVX groups (Fig. 3C ).
Exposure to chocolate and standard chow
When chocolate and standard chow were offered in the home cage, one-way ANOVA showed that the consumption of chocolate was higher in the E group, compared with the OVX, TAM and E + TAM groups (F(4,13) = 4.15, p = 0.02). No differences were seen among groups regarding the consumption of standard chow for 7 days (F(4,13) = 1.8, p = 0.19) (Fig. 4A) . During exposure to standard chow and chocolate, all groups showed an increase in total calories consumed per day and there were no significant differences among the groups (F(4,14) = 278, p b 0.001), unlike those observed when the animals were exposed only to standard chow (Fig. 4B) .
Although the same amounts of calories were consumed during the exposure to standard chow and chocolate, the OVX group showed the greatest weight gain and caloric efficiency, followed by the E, SHAM and TAM groups, while the E + TAM group presented weight loss (F(4,33) = 18.6, p b 0.0001) (Fig. 4C ) and lower caloric efficiency (F(4,10) = 24.67, p b 0.0001) (Fig. 4D) .
Blood Biochemistry
Ovariectomy caused an increase in total cholesterol (F(4,27) = 5.81, p = 0.001) and LDL cholesterol (F(4,27) = 5.72, p = 0.002) levels and this was prevented by the administration of estradiol and tamoxifen. The OVX, TAM and E + TAM groups demonstrated lower levels of HDL cholesterol (F(4,27) = 4.48, p = 0.006), compared to the SHAM and E groups. TAM treatment reduced triglyceride levels (F(4,27) = 5.77, p = 0.002) and prevented the effect of estradiol on this parameter. The TAM treatment group also presented the lowest plasma glucose levels, followed by E + TAM and estradiol groups (F(4,26) = 8.3, p b 0.001) . The OVX group showed a higher LDL/HDL ratio, compared with the other groups (F(4,27) = 4.7, p = 0.005) ( Table 3) . 
Discussion
Chronic treatment of ovariectomized rats with estradiol and tamoxifen led to a decrease in body weight, retroperitoneal fat and a decrease in standard chow intake. The caloric efficiency was lower for the E, TAM and E + TAM groups. When rats were exposed to a palatable food, a different profile was observed depending on the type of palatable food. The E, TAM and E + TAM groups consumed more Froot Loops® than the other groups. With regard to chocolate, the E group consumed more calories from chocolate, when compared with OVX, TAM and E + TAM groups. Chronic treatment with estradiol and tamoxifen showed a favorable lipid profile; low levels of TC, LDL, LDL/HDL ratio and lower levels of glucose were observed. Levels of HDL were lower in the OVX, TAM and E + TAM groups. The E group showed higher levels of TG and HDL, in contrast to the TAM and E + TAM groups.
Although tamoxifen is considered an estrogen agonist in the uterine tissue in women [41] , the present study showed that tamoxifen, in contrast to estradiol, was unable to revert the uterine weight loss induced by ovariectomy, and also inhibited the effect of estradiol. These results are in agreement with another study showing that tamoxifen has no effect on uterine weight [18] . However, other studies have shown that tamoxifen could partially reverse the uterine weight loss provoked by ovariectomy [42, 43] . The reason for these contradictory results on uterine weight is not well understood, because TAM was effective as an estrogen agonist when measuring the parameters, body weight loss and retroperitoneal fat (see below).
Ovariectomized rats and the SHAM group, which received the vehicle, presented increased body weight and retroperitoneal fat, whereas rats treated with estradiol and/or tamoxifen showed a reduction in these parameters. These results are consistent with previous findings in the literature [10, 18, 19, 21, 34, 35] . Estradiol and tamoxifen treatment provoked a decrease in standard chow intake in ovariectomized rats, as expected and in agreement with data from literature [18, 19, 21, 44] . The decrease in food intake associated with TAM and E treatment undoubtedly contributed to the decrease in body weight and fat content, but it is not clear whether hypophagia can entirely explain the weight loss [18] . An important role of the estradiol receptors (ERs), particularly ERα, in the reduction of body weight, food intake and adipose tissue has been demonstrated [15, [45] [46] [47] . Adipocytes isolated from obese women have been reported to present reduced ERα mRNA levels, compared to those of non-obese women, suggesting that estrogen signaling, in particular via ERα, may influence body weight [46] . ERα-deficient mice exhibited an increased adipose tissue mass without displaying differences in energy intake, suggesting that the weight gain is due to a decrease in energy expenditure [10, 48] . This could explain the low caloric efficiency of animals treated with estradiol and tamoxifen, found in the present study. Since tamoxifen, as well as estradiol, prevented any further weight gain, fat gain and food intake, it may be suggested that tamoxifen acts as an estradiol agonist on these parameters via ERα activation, given that tamoxifen is considered a partial agonist of ERα [11] . In addition, estradiol and tamoxifen reduce lipoprotein lipase activity [49] [50] [51] , which could contribute to decreased fat deposition due to reduced fatty acid release for lipogenesis. In addition, weight loss may be due to the role of estrogen in modulating uncoupling protein (UCP) in white adipose tissue. Estrogen can increase the expression of UCP2 in white adipose tissue and increase the energy spent as heat [52] . We also found differences in the palatable food intake profile when rats were submitted to different kinds of exposure to palatable foods (restrictive schedule to Froot Loops® or free access to chocolate). During the exposure to sweet food (Froot Loops®), after 5 days of food restriction and under a restrictive schedule of exposure to Froot Loops, rats treated with estradiol and/or tamoxifen increased their consumption, compared with the control groups. Other studies have also shown an increase in sweet food intake when estradiol levels are high, as seen in the proestrus in rats [27] and in the follicular phase in women [15] . When the animals were exposed to chocolate and standard chow in the home cage for 7 days with 24 h of free access, all groups consumed more chocolate than standard chow. In contrast, rats treated with estradiol ate even more chocolate than the OVX, TAM and E + TAM groups, although the total caloric consumption was the same in all groups. A similar observation was made by Boswell et al. (2006) [20] , who utilized a chocolate cake mix and observed an increase in food intake in rats treated with estradiol. On the other hand, Butera et al. (2010) [21] observed that estradiol treatment caused a reduction in chocolate intake, in a treatment paradigm that mimics the estrous cycle, instead of continuous hormone replacement. Therefore, we found that tamoxifen acted in a different manner, depending on the kind of palatable food and/or the paradigm of exposure to food.
Independently of sex, both rats and humans are naturally more susceptible to palatable foods. Food intake is regulated by several factors; a homeostatic pathway that maintains energy sources and a hedonic pathway that stimulates the desire to consume foods that are palatable [23] . Palatable food can mobilize opioids and dopamine and increase the levels of galanin, enkephalin, and orexin in the reward system, stimulating overeating as a positive feedback [23, 25] . Estrogen is also able to interact with the reward system by increasing the expression of orexin and galanin neurons in the hypothalamus, which are involved in reward-based feeding behavior [53] [54] [55] [56] . The activation of these neurons promotes the release of dopamine and an increase in palatable food intake [25, 53, 54] . This stimulation in reward circuitry may occur through ERβ, given that this receptor is able to modulate the dopamine receptor and dopamine transporter in the striatum and accumbens nucleus [13] and it is probably the estradiol receptor more related to the ingestion of palatable foods [27] . Tamoxifen is known to have antagonist effects in ERβ [11] , and this could explain the difference in chocolate intake between the tamoxifen and estradiol groups. In this sense, we speculate that estradiol could increase palatable food ingestion by stimulation of the release of hormones and neuropeptides involved in reward circuitry, independently of the satiety system; such an effect may occur through ERβ. In addition, the TAM and E + TAM groups consumed the same calories as the other groups during the exposure to chocolate, but demonstrated a lower caloric efficiency.
Evaluation of Froot Loops consumption, unlike the evaluation of chocolate consumption, involved a habituation period (5 days) and during this period the animals were deprived of food (80%). On the test day the animals were fed, but consumption was assessed as before, using a restrictive schedule. Food deprivation strongly augments the reward value (for example, the speed of learning to obtain a rewarding stimulus) [57] . However, the OVX and SHAM groups showed a significantly higher latency to eat and ate less, compared with groups treated with estradiol and/or tamoxifen. Independently from the hormonal milieu of the animal, food deprivation increases the expression of neuropeptides Y (NPY) in the arcuate nucleus, consequently more NPY is released in the paraventricular nucleus [58] and these effects can be reversed by leptin administration [59] . Furthermore, estradiol treatment reduces the circulating leptin levels, and increases the leptin receptor and suppressor of cytokine signaling 3 (SOCS3, an inhibitor of leptin signaling) expressions in the medial basal hypothalamus; however these effects were not observed in OVX rats treated with vehicle [44] . Given that NPY is related to the increase in high carbohydrate diet consumption [60] , the food deprivation that rats underwent during the habituation period might have been responsible for the higher consumption of Froot Loops in rats treated with estradiol and tamoxifen. This effect was not observed in the SHAM and OVX groups, probably due to the high circulating leptin levels (which inhibit NPY), given that these groups have a higher fat accumulation. NPY declines in relation to body fat, presumably attributable to an increase in leptin levels [60] . Further studies are needed to elucidate the mechanisms involved in the effects of estradiol and tamoxifen on palatable food behavior.
Estradiol and tamoxifen treatment showed a favorable profile regarding plasma lipids and glucose. The estradiol and tamoxifen groups presented a decrease in TC, LDL levels, and LDL/HDL ratio and plasma glucose, compared to the OVX rats treated with vehicle; however, the effect of TAM was more accentuated on TC and glucose levels. The TAM and OVX groups presented lower HDL cholesterol levels, compared with the estradiol group; however the difference in LDL/HDL ratio in OVX rats was probably due to the high levels of LDL in this group. The decrease in plasma LDL caused by estradiol may be the result of increased hepatic LDL receptor expression [61] [62] [63] which increases the clearance of plasma LDL and the secretion of cholesterol into the bile. In addition, it has been demonstrated that this LDL receptor transcription activation occurs via ERα [63] , therefore, tamoxifen may act by the same mechanism, increasing hepatic LDL receptor expression [64] with a consequent decrease in LDL levels. With regard to HDL levels, estrogen is known to increase plasma levels of HDL cholesterol [65, 66] . This may be due to an increase of hepatic apo A-I expression [67, 68] and by a modulation of the proteins involved in the metabolism of HDL expression, such as HDL receptor SR-BI [69, 70] . However, the effect of tamoxifen is less conclusive, because literature reports increase [71] , decrease [64] , or no change [72] on HDL cholesterol levels. Moreover, differently from estradiol treatment, the levels of SR-BI expression were not changed with tamoxifen treatment [64] . However, despite the lower levels of HDL shown in TAM group, the LDL/HDL ratio was equal to the estradiol group and different from OVX rats treated with vehicle. It has been shown that estradiol induces a decrease in lipoprotein lipase (LPL) activity in adipose tissue [50, 73] and this mechanism could, at least in part, explain the elevated serum triglycerides found in estradiol group. Tamoxifen also reduces the LPL activity in humans and rats, but differently from estradiol, it did not elevate plasma triglyceride levels [51] , perhaps it can be due to a decrease in VLDL secretion. It has been demonstrated that tamoxifen induces hepatic triacylglycerol accumulation [64] , probably due to an increase in the synthesis [74] or a fatty acid oxidation blockade [64] . It could disturb the liver function and reduce the secretion of VLDL.
Conclusion
Tamoxifen treatment mimicked the effects of estradiol in many parameters: weight loss, retroperitoneal fat, standard chow intake and in most lipids analyzed, but in the uterine weight TAM behaved as estrogen-antagonist. Concerning the palatable food intake, TAM acted in a different manner depending on the experimental conditions. Under restrictive schedule, TAM treated rats ate as much Froot Loops as E group. Under free access, all groups showed more preference to chocolate than standard chow, but E group ate even more chocolate. Further, TAM group showed lower caloric efficiency irrespective of the kind of food offered (palatable or standard chow), showing that TAM group has greater energy expenditure and in consequence it accumulates less fat than the other groups.
